Selskabets formål er at drive handel og industri
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 1 mia. | 113.9 mio. | 3.1 mia. | 2.4 mia. | 529 | |
CVR: 13246149
Previous names: A/S PSE NR. 3369, FERROSAN FINE CHEMICALS A/S, FEF CHEMICALS A/S
9 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Novo Nordisk Pharmatech A/S demonstrates strong financial health with a notable upward trajectory in revenue and profit over recent years. Revenue increased from 598 million DKK in 2022 to over 1 billion DKK in 2025, while profit surged from 39 million DKK in 2022 to nearly 114 million DKK in 2025, indicating robust growth. The company's equity has also significantly improved, rising from 689 million DKK in 2022 to 2.44 billion DKK in 2025, reflecting a solid financial foundation. Key strengths include its increasing profit margins and strong equity position, although the absence of a calculated CDS score may raise some concerns regarding its debt profile. Positioned within the pharmaceutical manufacturing industry, the company is likely benefiting from growing demand for its products.
AI-generated summary
Companies in the same industry and area
Mette Sofie Mørck Jarl joined the board
Jean Fabian Jeldorf left the board
Mette Sofie Mørck Jarl left the board
Hazal Polat left the board
companydata.dk